404results about How to "Synergistic effect" patented technology

Disclosed are: a safe and highly effective prophylactic/ameliorating or therapeutic agent for NASH; and a method for using the agent. The prophylactic/ameliorating or therapeutic agent for NASH comprises a combination of at least one component selected from the group consisting of ω3PUFAs, a pharmaceutically acceptable salt thereof and an ester thereof and a PDE4 inhibitor as active ingredients.

The present invention concerns chimeric cancer therapeutic molecules comprising a targeting moiety and an anti-cell proliferation moiety. The anti-cell proliferation moiety may comprise a cytotoxic agent or an apoptosis-inducing factor, in specific embodiments. In particular embodiments, the anti-cell proliferation mechanism of the chimeric molecules comprises apoptotic pathways. In additional embodiments, the chimeric molecules of the present invention provide sensitivity to chemotherapy in a cell that is resistant to the chemotherapy.

A composition of probiotics, vitamins and minerals, electrolytes with glutamine and glucose along with medium chain triglycerides are provided as a supplement to animals. This is administered to cattle, calves, sheep, pigs, horses, dogs, and cats that are experiencing stress and or are undergoing medical drug therapy to treat conditions of diseases along with pre and post operative surgical conditions. The composition helps correct imbalances in beneficial bacteria, provides energy and helps in rehydration to reduce recovery time from stress or in disease treatment in these animals.

The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.

Antiviral compositions comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compositions.

A combination for surface treating powder, composed of (I)organopolysiloxane or condensate thereof and (II)organopolysiloxane in a weight ratio of (I):(II) of from 95:5 to 5:95; (I)organopolysiloxane or condensate thereof and (III) acryl/silicone copolymer in a weight ratio of (I):(III) of from 95:5 to 5:95; or (I)organopolysiloxane or condensate thereof, (II)organopolysiloxane and (III) acryl/silicone copolymer in a weight ratio of (I):[(II)+(III)] of from 95:5 to 5:95, provided that each of (I), (II), and (III) may be packed together or separately, wherein (I)organopolysiloxane is represented by the following formula (1),

R¹_a(OR²)_bSiO_(4-a-b)/2  (1)

wherein R¹ may be the same with or different from each other and is a C_1-30 alkyl, aryl, aralkyl, fluorinated alkyl or amino-substituted alkyl group,

• R² is a C_1-6 alkyl group, a is the number of from 0.75 to 1.5, and b is the number of from 0.2 to 3, provided that a sum of a and b is greater than 0.9 and at most 4; (II)organopolysiloxane is represented by the formula (2)

R³_cR⁴_dR⁵_eSiO_(4-c-d-e)/2  (2)

wherein R³may be the same with or different from each other and is a C_1-30 alkyl, aryl, aralkyl, or fluorinated alkyl group,

R⁴ is a hydrogen atom, a hydroxyl group or a C_1-6 alkoxy group and is bonded to the Si atom in the formula (2) via a group comprising carbon, oxygen, or silicon atom, and

R⁵ is a silicone compound residue represented by the following formula

wherein R3 is as defined above, c is the number of from 1.0 to 2.5, d is the number of from 0.001 to 1.5, and e is the number of from 0 to 1.5, x is an integer of from 1 to 5, and y is an integer of from 0 to 500; and (III) acryl/silicone copolymer has at least one hydrolyzable silyl group.

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time.

Embodiments of the present invention generally comprise compositions comprising benzimidazole, avermectin and praziquantel for the control of various parasites and for the prevention of heartworm disease in dogs.

Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

The present invention is directed to a pharmaceutical preserving composition comprising: (a) at least one chitosan or chitosan derivative and (b) at least one buffer solution, as well as methods of preserving contact lens solutions and disinfecting contact lens using such composition. The present invention is further directed to a method of preparing O-acetylated chitosan or chitosan derivatives comprising the steps of dissolving the chitosan or chitosan derivative into an aqueous acidic solution and reacting the chitosan or chitosan derivative with an acetylating agent in the presence of a phase transfer reagent.

The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: Clostridium-like species, Prevotella-like species, Bacteroides-like species, Enterococcus-like species, Selenomonas species, non-dextran slime producing Streptococcus species and non-slime producing lactic acid bacterial isolates.

An olefinically unsaturated monomer is stabilized by a retarder-containing composition which comprises a solvent and a quinone methide as a retarder.

The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

A sugar replacement includes a mixture of agave inulin and agave fructose. The agave inulin forms from 40 to 90 percent by weight of the sugar replacement. The agave fructose forms a remainder (10 to 60 percent by weight) of the sugar replacement. The sugar replacement has reduced calories and glycemic index compared to sugar. The sugar replacement can have its sweetness adjusted so that it is a one to one replacement for sugar. This is particularly useful when the sugar replacement is being used in baking recipes. Baked goods and caramels using the sugar replacement have qualities like those using sugar. The sugar replacement can be used to make chocolates.

The invention provides bacillus subtilis DLD2 bacterial strain which is preserved in a China general microbiological culture collection center (CGMCC), the serial number is CGMCC NO.3222. The invention further provides a multi-functional biological agent formula and a preparation method thereof; fermentation broth, fulvic acid, zinc sulfate and other components of the bacillus subtilis DLD2 are formulated for preparing the multi-functional biological agent formula which is used for improving soil and continuous cropping resistance; the biological agent has the following functional effect: (1) bio-control microorganisms are utilized to prevent harmful flora from infecting plant and killing pathogenic bacteria, induce the plant to generate disease resistance and prevent seedling withering and rotting; (2) by utilizing synergia effect of formulation of the bacillus subtilis, fulvic acid and zinc sulfate, the root system growth can be induced, plant regeneration and root regeneration are realized, soil hardening is broken, granular structure is formed, no deep tillage is realized, moisture holding and soil moisture conservation is realized, fertilizer damage is relieved and soil fertility is improved.

The invention discloses a ZnO-Ag surface enhanced Raman scattering substrate and detection of organic pollutants with the substrate. The preparation method for the substrate comprises the following steps: the first step, ITO conductive glass is subjected to ultrasonic cleaning with acetone, alcohol and deionized water one by one and dried in the air; the second step, organic additives are added in a zinc nitrate solution, a first mixed liquid is formed, after the first mixed liquid is stirred for 30 min, an ammonia-water solution with a mass fraction of 25% is dropwisely added in the first mixed liquid, a second mixed liquid is formed, the processed ITO conductive glass from the first step is soaked in the second mixed liquid, after the water bath is at a constant temperature, the ITO conductive glass is placed in a baking box and baked for 60-100 min, a white and uniform ZnO layer is formed on the surface of the ITO conductive glass; the third step, Ag nanoparticles are deposited on the prepared ZnO nanolayer from the second step, and a ZnO-Ag surface enhanced Raman scattering substrate is obtained. The preparation method is simple. The prepared substrate has high sensitivity and good stability and can be used repeatedly.

The invention discloses a diversification premixing modified starch and a relative production method, which premixes etherified-crosslink-esterified starch, esterified-esterified starch and esterified-crosslink starch which are produced independently in a certain ratio, to obtain the starch with good freeze stability, gel property, and water retention. The product supplies a new processing property for modified starch product, which can be applied for food, particularly for low-temperature meat product, to adhere, stuff and improve water retention. The invention has short production period, low energy consumption, simple operation and high product stability.

The invention provides sorghum wine and a preparation method thereof. The preparation method comprises the following steps of: selecting sorghums not to be peeled, boiling in water till sorghum peels are broken, and filtering to obtain peel broken sorghums; steaming the peel broken sorghums to obtain cooked sorghums; adding distiller yeast into the cooked sorghums, and fermenting at 30-40 DEG C for 72-90h so as to obtain fermented sorghums; and immersing the fermented sorghums by using sorghum liquor for 5-9 days, and taking out supernate to obtain the sorghum wine, wherein in terms of weight, the proportion of the sorghums, the distiller yeast to the sorghum liquor is 1:(0.0015-0.002):(1.2-1.6). According to the invention, the traditional sorghum liquor is deeply processed; the nutritive value and the mouth feel are improved; furthermore, by uniquely adopting the steaming and boiling combined manner, the extraction rates of nutritional components are increased; the fermentation effect is improved; simultaneously, the high-quality fermented sorghums are obtained by adopting a unique fermentation condition; and the high-quality fermented sorghums can be mutually fused with the sorghum liquor so as to generate synergistic effects.

The invention provides a soil improvement and anti continuous cropping multifunctional biological agent which contains the mixed microorganism of trichoderma pseudokoningii and bacillus subtilis, faveolate humic acid and zinc sulphate; the trichoderma pseudokoningii is a bacterial strain obtained by separating and screening maize straw; the bacterial strain is named after (Trichoderma pseudokoningii) DLDI and is preserved in China general microbiological culture collection (CGMCC), and the number thereof is CGMCC NO.3221; the bacillus subtilis obtained by separating soil is named after (bacillus subtilis) DLD2 and is preserved in China general microbiological culture collection (CGMCC), and the number is CGMCCNO.3222; the biological agent has the effects that (1) biocontrol microorganism is used for blocking harmful flora from infecting plants and killing pathogenic bacteria, induces the plants to generate disease resistance and prevents dead seedlings from rotting roots; (2) the microorganism and the faveolate humic acid are compounded to induce the root system to grow, thus realizing root regeneration and plant regeneration and inhibiting the anti continuous cropping diseases; and (3) the faveolate humic acid and the zinc sulphate are used for breaking the soil hardening of the soil, forming the crumble structure, realizing no deep ploughing, retaining water, alleviating fertilizer damage and increasing the soil productivity.

The invention relates to the technical field of food and in particular discloses crystal mochi preblended flour, crystal mochi and a preparation method thereof. The crystal mochi preblended flour is prepared from the following raw materials in parts by weight: 10-15 parts of hydroxypropyl distarch phosphate, 8-13 parts of acetylated distarch phosphate, 0.5-0.7 part of maltitol, 0.2-0.4 part of monoglyceride, 0.04-0.06 part of sodium dehydroacetate and 0.04-0.06 part of citric acid. The crystal mochi is characterized in that a wrapper of the crystal mochi is prepared from raw materials, namely the crystal mochi preblended flour disclosed by the invention, water, emulsified oil and malt syrup. The mochi disclosed by the invention does not harden during storage, has good freeze-thaw stability, does not crack or collapse after being thawed, can maintain the original smooth and glutinous tastes and is long in quality guarantee period; and the prepared mochi is glittering and translucent in appearance and is soft, strong and not sticky and does not stick the mouth when entering the mouth, and the prepared mochi has good elasticity.

The present invention is directed to a water soluble, randomly substituted partial N-, partial O-acetylated chitosans or chitosan derivatives and methods of preparing water soluble, randomly substituted partial N-, partial O-acetylated chitosans or chitosan derivatives comprising the steps of dissolving the chitosan or chitosan derivative into an aqueous acidic solution and reacting the chitosan or chitosan derivative with an acetylating agent in the presence of a phase transfer reagent. The present invention is further directed to a pharmaceutical preserving composition comprising: (a) at least one chitosan or chitosan derivative and (b) at least one buffer solution, as well as methods of preserving contact lens solutions and disinfecting contact lens using such composition.

New compositions and methods for treating patients suffering from hepatitis-C, AIDS, aberrant apoptosis which include N-acetyl-D-glucosaminyl(beta-1-4)-N-Acetyl-muramyl-L-ananyl-D-isoglutamine (GMDP) of at least 98% purity and provided either alone, as an active ingredient of blastolysine, or in combination with an aminosugar such as N-acetyl-glucosamine(NAG). The high purity GMDP has a decreased amount immunogenic impurities and demonstrates cell protection as opposed to solely immunostimulatory effects, while a synergistic cell protective effect is exhibited when GMDP in combined with NAG. The new compositions modulate FasL mediated apoptosis while simultaneously stimulating TNF-alpha production and further selectively inhibiting TNF-alpha receptor p55 (TNFR1), providing a treatment for patients suffering from hepatitis-C, AIDS or aberrant apoptosis.

The invention discloses a corrosion inhibitor composition, which includes a main agent and a compounded agent. The main agent is selected from the group consisting of oleic acid based imidazoline, naphthenic imidazoline, and bis-imidazoline. The compounded agent is selected from amino tris(methylene phosphonic acid), hydrolyzed polymaleic anhydride, sodium of polyaspartic acid and 2-phosphonobutane-1, 2, 4-tricarboxylic acid. Specifically, the main agent and compounded agent are in a mass ratio of 1:5-5:1. The corrosion inhibitor composition provided in the invention is compounded by the main agent and the compounded agent in a reasonable proportion, and a synergistic effect is achieved.